Barclays reaffirms its 'weight in line' recommendation on Roche, while lowering its target price from 250 to 230 Swiss francs, the day after the Swiss healthcare group's first-quarter trading update.

"Although Roche's sales report came out in line and forecasts were unchanged, the conference focused on competitive threats to the major franchises", reports the broker.

With Phase III results for Novo Nordisk's Mim8 in hemophilia A imminently expected, we think the stock could be held in a narrow range until then', continues Barclays.

Copyright (c) 2024 All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.